Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial

Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial

Blog Article

Abstract Background Patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC, 15.4 vs.4.

07 months).We conducted Fabric Wall Hanging an economic evaluation of pralatrexate from a societal perspective in Korea based on data from the PROPEL phase II study.Methods Using a Markov model with a weekly cycle, we simulated the experience of patients with R/R PTCL receiving pralatrexate or CC for 15 years.

The model consists of five health states; initial treatment, treatment pause, subsequent treatment, stem cell transplantation (SCT) success, and death.Comparative effectiveness was based on PROPEL phase II single-arm study and its matched historical control analysis.Costs included drug, drug administration, monitoring, adverse event management, and SCT costs.

Results The incremental cost-effectiveness ratio of the base case was $39,153 per quality-adjusted life-year (QALY) gained.The results of one-way sensitivity analysis ranged from $33,949 to $51,846 per QALY gained, which remained within an implicit willingness-to-pay (WTP) threshold of Lotion anticancer drugs in Korea.Conclusions Pralatrexate is a cost-effective intervention with improved OS and incremental costs within the WTP limit.

Pralatrexate could function as a new therapeutic option for patients suffering from life-threatening R/R PTCL.